WO2019199260A2 - Formulations comprenant des extraits d'herbes - Google Patents

Formulations comprenant des extraits d'herbes Download PDF

Info

Publication number
WO2019199260A2
WO2019199260A2 PCT/TR2018/050927 TR2018050927W WO2019199260A2 WO 2019199260 A2 WO2019199260 A2 WO 2019199260A2 TR 2018050927 W TR2018050927 W TR 2018050927W WO 2019199260 A2 WO2019199260 A2 WO 2019199260A2
Authority
WO
WIPO (PCT)
Prior art keywords
extract
formulation
formulation according
mixtures
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2018/050927
Other languages
English (en)
Other versions
WO2019199260A3 (fr
Inventor
Ali TÜRKYILMAZ
Seval Ataman
Gülay Yelken
Mustafa MARASLI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Montero Gida Sanayi Ve Ticaret AS
Original Assignee
Montero Gida Sanayi Ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Montero Gida Sanayi Ve Ticaret AS filed Critical Montero Gida Sanayi Ve Ticaret AS
Publication of WO2019199260A2 publication Critical patent/WO2019199260A2/fr
Publication of WO2019199260A3 publication Critical patent/WO2019199260A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/577—Malvaceae (Mallow family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Definitions

  • Echinacea purpurea the purple coneflower, is a plant species widely used in the prophylaxis and/or treatment of infection, cold, cough, bronchitis, flu, in the treatment of infection of the urinary system, in the treatment of the sore throat and toothache, in boosting the immune system, and externally, in the treatment of snakebite, eczema, psoriazis, acne, wounds and burns.
  • Echinacea purpurea is known to have immunostimulant, anti-inflammatory, antibacterial, antiviral, antifungal, anticancer, cicatrizant activities.
  • Ginseng root is harvested after a cultivation period of 6 years and this part of the plant is used for therapeutic purposes. It comprises saponins (dammaran and oleanan derivatives; ginsenosites), polyacetylene derivatives and polysaccarides.
  • saponins dammaran and oleanan derivatives; ginsenosites
  • polyacetylene derivatives polysaccarides.
  • the effects of Ginseng on the body are not local, and thus, one of the benefits of Ginseng is that it strengthens the entire body and helps in balancing entire body systems.
  • Ginseng is an antioxidant and an important immunity system improver which increases the number of immunity system cells in the body. It is useful in the treatment of bronchitis, asthma and circulation problems.
  • the flu risk of people who are administered 200mg ginseng root capsules twice a day reduced by 31%. In the laboratory and animal experiments, it is found that it is effective against prostate, stomach, kidney, liver, large intestine, brain and lung cancer
  • Honey is the natural product processed by honeybees from flower nectars or plant secretions, by aid of their own secretions.
  • Honey is a nutritious, sweet and healthy food, and minor components of honey include proteins (0.25-0.5%), organic acids, aminoacids, vitamins, flavonoids and water.
  • the amount of water in honey is between 15.00% and 30.00% by weight.
  • Another object of the present invention is to provide formulations with a significantly improved stability, as well as the excellent long-term stability.
  • Yet another object of the present invention is to develop formulations which are capable of providing an easy administration accompanied by an increased patient compliance and convenience.
  • a further object of the present invention is to provide an improved oral film formulation of pelargonium sidoides extract and propolis extract.
  • a further object of the present invention is to provide stable oral film dosage forms by making use of convenient excipients, which do not stick to each other, and have a taste which is not unpleasant, comprising pelargonium sidoides extract and propolis extract.
  • the amount of berberis vulgaris in the formulation is between 0.01 % and 1 .00% by weight of total formulation.
  • the amount of berberis vulgaris in the formulation is between 0.01 % and 0.20% by weight of total formulation.
  • the additional herbal extract is tilia.
  • a. pelargonium sidoides extract 0.1% to 1.00%
  • honey is in natural form. Using natural honey also increases the stability of the formulation due to its protective properties and long shelf-life.
  • Suitable plasticizers are selected from a group comprising glycerin, monopropylene glycol, polyethylene glycol, dibutyl phthalate, triacetin, castor oil, dimethyl phthalate, diethyl phthalate, dibutyl phthalate, tributyl citrate, triethyl citrate, acetyl citrate or mixtures thereof.
  • the amount of glycerin in the formulation is between 1 .00% and 35.00%, the amount of monopropylene glycol is between 1 .00% and 35.00% by weight of total formulation.
  • a solid dispersion of the active agent is prepared together with other materials in the formulation and then processed in a hot melt extrusion device.
  • the resulting product is turned into the oral films. Then the film is cooled and cut into a desired size and shape.
  • Example 1 Oral film

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Insects & Arthropods (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne des formulations comprenant un extrait de Pelargonium sidoides et un extrait de Propolis pour fournir un traitement dans diverses maladies respiratoires telles que le rhume, la toux, l'asthme allergique, la rhinite allergique saisonnière, la bronchite, la pharyngite, la laryngite et la pneumonite.
PCT/TR2018/050927 2017-12-29 2018-12-28 Formulations comprenant des extraits d'herbes Ceased WO2019199260A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR2017/22959A TR201722959A2 (tr) 2017-12-29 2017-12-29 Bi̇tki̇sel ekstreler i̇çeren kati oral formülasyonlar
TR2017/22959 2017-12-29
TR2018/04828A TR201804828A2 (tr) 2017-12-29 2018-04-05 Bi̇tki̇ ekstraktlari i̇çeren formülasyonlar
TR2018/04828 2018-04-05

Publications (2)

Publication Number Publication Date
WO2019199260A2 true WO2019199260A2 (fr) 2019-10-17
WO2019199260A3 WO2019199260A3 (fr) 2020-02-20

Family

ID=67900929

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/TR2018/050920 Ceased WO2019209227A2 (fr) 2017-12-29 2018-12-27 Formulations orales solides comprenant des extraits d'herbes
PCT/TR2018/050928 Ceased WO2019209229A2 (fr) 2017-12-29 2018-12-28 Formulations topiques comprenant des extraits d'herbes
PCT/TR2018/050927 Ceased WO2019199260A2 (fr) 2017-12-29 2018-12-28 Formulations comprenant des extraits d'herbes

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/TR2018/050920 Ceased WO2019209227A2 (fr) 2017-12-29 2018-12-27 Formulations orales solides comprenant des extraits d'herbes
PCT/TR2018/050928 Ceased WO2019209229A2 (fr) 2017-12-29 2018-12-28 Formulations topiques comprenant des extraits d'herbes

Country Status (2)

Country Link
TR (3) TR201722959A2 (fr)
WO (3) WO2019209227A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112587487A (zh) * 2020-11-30 2021-04-02 建昌帮药业有限公司 一种松果菊苷口崩片及制备方法
CN113481612A (zh) * 2021-07-02 2021-10-08 南通大学 一种纳米纤维膜复合面料的制备工艺
WO2021221577A3 (fr) * 2020-04-27 2022-11-03 Montero Gida Sanayi Ve Ticaret Anonim Sirketi Formulations de complément alimentaire comprenant un édulcorant naturel
CN115428869A (zh) * 2022-09-02 2022-12-06 南京农业大学 一种改善肉鸡肠道健康的生物制剂及其制备方法和应用
CN116419758A (zh) * 2020-11-04 2023-07-11 巴布西尔韦有限责任公司 抗菌组合成分
IT202200004958A1 (it) * 2022-03-16 2023-09-16 Neilos S R L “Composizione nutraceutica o farmaceutica per il benessere renale”
DE202024107221U1 (de) 2024-12-12 2025-01-14 Little Umbrella Limited Zusammensetzung, die neuseeländische Boysenbeere und eine Vielzahl von Pflanzen zur Linderung von Husten und zum Schutz der Lunge enthält

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2716162C1 (ru) * 2019-11-19 2020-03-06 Федеральное государственное бюджетное учреждение науки Федеральный научный центр "Владикавказский научный центр Российской академии наук" (ВНЦ РАН) Способ лечения хронического генерализованного пародонтита легкой степени тяжести
FR3124378B1 (fr) * 2021-06-24 2024-10-25 Bobs Silver Composition antiseptique pour administration nasale
FR3115683A1 (fr) * 2020-11-04 2022-05-06 Bobs Silver Composition antiseptique pour administration nasale
GB2623801A (en) * 2022-10-27 2024-05-01 Alex Fabian Smith Composition and method for reducing negative taste sensations of propolis preparations
GR1010684B (el) * 2023-04-12 2024-05-13 Ιουλια Κλεωνος Τσετη Συνθεση για την καταπραϋνση της στοματοφαρυγγικης κοιλοτητας και του λαιμου και την ενισχυση του ανοσοποιητικου συστηματος
WO2025114598A1 (fr) * 2023-11-30 2025-06-05 Nyx-Medico Aps Composition comprenant des extraits d'herbes pour atténuer le ronflement

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1274796B (it) * 1994-12-23 1997-07-24 Stefano Verardi "cerotto per assorbimento transcutaneo a rilascio controllato di estratti di sostanze naturali"
US6197305B1 (en) * 1998-01-05 2001-03-06 Farmo-Nat Ltd. Anti-fungal compositions with prolonged activity
WO2006079109A2 (fr) * 2005-01-21 2006-07-27 Rdx Technologies, Inc. Compositions antimicrobiennes non toxiques, et procedes d'utilisation de polyphenols pro-oxydatifs et d'antioxydants
EP1685875A1 (fr) * 2005-01-28 2006-08-02 Gumlink A/S Chewing gum de soins buccaux à plusieur fonctions
US9913869B2 (en) * 2012-10-18 2018-03-13 Montero Gida Sanayi Ve Ticaret A.S. Formulations comprising herbal extracts
EP2937077B1 (fr) * 2014-04-24 2021-10-06 Montero Gida Sanayi Ve Ticaret A.S. Formulations orales liquides comprenant des extraits d'herbes
US11623008B2 (en) * 2014-08-20 2023-04-11 Professional Compounding Centers Of America Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan
CA2973217A1 (fr) * 2015-02-11 2016-08-18 The Fix, Llc Compositions et procedes d'administration d'une association d'ingredients
CN104996994A (zh) * 2015-04-24 2015-10-28 劲膳美生物科技股份有限公司 慢性阻塞性肺疾病特定全营养配方食品
CN106727990A (zh) * 2017-02-14 2017-05-31 哈尔滨市第医院 口腔护理液及其制备方法
CN107510778B (zh) * 2017-09-01 2020-10-09 河南科技大学 一种清肺防霾饮及其制备方法

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021221577A3 (fr) * 2020-04-27 2022-11-03 Montero Gida Sanayi Ve Ticaret Anonim Sirketi Formulations de complément alimentaire comprenant un édulcorant naturel
CN116419758A (zh) * 2020-11-04 2023-07-11 巴布西尔韦有限责任公司 抗菌组合成分
US20230405044A1 (en) * 2020-11-04 2023-12-21 Bobs Silver Antiseptic composition
CN112587487A (zh) * 2020-11-30 2021-04-02 建昌帮药业有限公司 一种松果菊苷口崩片及制备方法
CN112587487B (zh) * 2020-11-30 2022-08-16 建昌帮药业有限公司 一种松果菊苷口崩片及制备方法
CN113481612A (zh) * 2021-07-02 2021-10-08 南通大学 一种纳米纤维膜复合面料的制备工艺
CN113481612B (zh) * 2021-07-02 2022-06-28 南通大学 一种纳米纤维膜复合面料的制备工艺
WO2023273955A1 (fr) * 2021-07-02 2023-01-05 南通大学 Procédé de préparation d'un tissu composite à membranes de nanofibres
IT202200004958A1 (it) * 2022-03-16 2023-09-16 Neilos S R L “Composizione nutraceutica o farmaceutica per il benessere renale”
CN115428869A (zh) * 2022-09-02 2022-12-06 南京农业大学 一种改善肉鸡肠道健康的生物制剂及其制备方法和应用
CN115428869B (zh) * 2022-09-02 2024-01-05 南京农业大学 一种改善肉鸡肠道健康的生物制剂及其制备方法和应用
DE202024107221U1 (de) 2024-12-12 2025-01-14 Little Umbrella Limited Zusammensetzung, die neuseeländische Boysenbeere und eine Vielzahl von Pflanzen zur Linderung von Husten und zum Schutz der Lunge enthält

Also Published As

Publication number Publication date
WO2019209229A2 (fr) 2019-10-31
TR201804828A2 (tr) 2019-07-22
TR201809956A2 (en) 2019-07-22
WO2019209227A2 (fr) 2019-10-31
WO2019209229A3 (fr) 2020-01-30
TR201722959A2 (tr) 2019-07-22
WO2019209227A3 (fr) 2020-01-23
WO2019199260A3 (fr) 2020-02-20

Similar Documents

Publication Publication Date Title
WO2019209229A2 (fr) Formulations topiques comprenant des extraits d'herbes
EP2908834B1 (fr) Nouvelles formulations comprenant des extraits de plantes
EP2908833B1 (fr) Formulations comprenant des extraits de plantes
US20160331794A1 (en) Composition for use in the treatment of persistent cough
EP2908831B1 (fr) Formulations à base de plantes médicinales
US20170182105A1 (en) Orodispersible film
EP2908835B1 (fr) Formulations stables
CN101095827A (zh) 治疗咽喉疾病的中药制剂及其制备方法
WO2019209228A2 (fr) Compositions orales solides comprenant du miel séché et des extraits d'herbes
WO2021221577A2 (fr) Formulations de complément alimentaire comprenant un édulcorant naturel
KR20150084919A (ko) 이부프로펜 나트륨 이수화물 기반의 의약 로젠지
Sahoo et al. The research updated and prospects of herbal hard-boiled lozenges: a classical platform with promising drug delivery potential
CN103623203B (zh) 一种咳舒口服制剂的制备方法
CN120459245A (zh) 一种口腔含片及其制备方法
Pashikanti et al. Formulation and Evaluation of Guaifenesin Hard Candy Lozenges
CN119424588A (zh) 一种用于治疗鼻腔炎症性疾病的中药组合物、制剂及其应用
BR102015033039B1 (pt) Processo de obtenção de micropartículas matriciais de própolis (extrato seco), micropartículas matriciais de própolis (extrato seco) obtidas, formulações compreendendo as mesmas e seus usos

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18914443

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18914443

Country of ref document: EP

Kind code of ref document: A2